Subcutaneous Recombinant Interleukin-2 Plus Chemotherapy with Cisplatin and Dacarbazine in Metastatic Melanoma

M. Guida, A. Latorre, A. Mastria, M. De Lena

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of our study was to verify the efficacy and tolerability of subcutaneous low doses of interleukin-2 with cisplatin and dacarbazine for malignant melanoma. 24 patients were included. The following schedule was used: cisplatin (CDDP) 100 mg/m2 day 1; darcarbazine (DTIC) 375 mg/m2 days 1-5; recombinant interleukin-2 (rIL-2) 4.5 million IU × 2/day days 13-17 and 20-24. The therapy was recycled every 28 days. 10 patients obtained clinical remission (42%), with 2 complete responses (8%) persisting for 12 and 15+ months, and 8 partial responses (35.5%) with a median duration of 5 months. Median survival of all 24 patients was 8 months, 13 months for responders and 6 months for non-responders. Responses were seen predominantly in lymph nodes (48%) and skin-soft tissue (38%), but were also seen in the liver (29%) and lung (14%). Treatment was relatively well tolerated and toxicity was mainly related to chemotherapy.

Original languageEnglish
Pages (from-to)730-733
Number of pages4
JournalEuropean Journal of Cancer
Volume32
Issue number4
DOIs
Publication statusPublished - Apr 1996

Keywords

  • CDDP + DTIC + subcutaneous IL-2
  • Metastatic melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Subcutaneous Recombinant Interleukin-2 Plus Chemotherapy with Cisplatin and Dacarbazine in Metastatic Melanoma'. Together they form a unique fingerprint.

Cite this